Key statistics
On Friday, InnoCare Pharma Ltd (33C:MUN) closed at 1.38, 100.00% above the 52 week low of 0.69 set on Feb 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.38 |
|---|---|
| High | 1.38 |
| Low | 1.38 |
| Bid | 1.33 |
| Offer | 1.43 |
| Previous close | 1.26 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 1.76bn |
| Free float | 1.20bn |
| P/E (TTM) | -- |
| Market cap | 26.44bn HKD |
| EPS (TTM) | -0.1389 HKD |
Data delayed at least 15 minutes, as of Feb 06 2026 07:01 GMT.
More ▼
Announcements
- Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
- InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
- InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
- InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
- InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
- Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
- Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
- InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
- InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China
- Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025
More ▼
